The Moderna vaccine is being sent to Vietnam by the United States. Photo: AFP / Jakub Porzycki / NurPhoto

Europe’s major stock markets spiked Monday after Moderna announced its experimental Covid-19 vaccine was shown to be 94.5 percent effective according to early trial results, sparking fresh hope of a return to normality.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.

European equities accelerated gains on the news, which comes just one week after Pfizer and BioNTech sparked a stock market boom after announcing that their vaccine candidate had proved 90 percent effective.

Shortly after midday on Monday, London stocks were up 1.7 percent, extending early gains.

In early afternoon deals in the eurozone, Frankfurt added 1.2 percent and Paris soared 2.4 percent, while Madrid and Milan jumped 3.9 percent and 2.3 percent, respectively.

End of nightmare

“Just as their initial dose of vaccine bullishness appeared to be waning, the markets got another injection of good news this Monday,” Spreadex analyst Connor Campbell said.

“One-upping BioNTech and Pfizer, Moderna has claimed its preparation is nearly 95 percent effective after a trial involving 30,000 Americans.

“As with Pfizer, there is still a way to go before Moderna’s vaccine is approved. However, investors were only thinking about the long-term, flashing forward to the end of this nightmare.”

World oil prices soared by more than 3.5 percent as the Moderna news stoked hopes of a recovery in energy demand.

Prior to the midday announcement, global stock markets were already staging a rally on bright economic data and last week’s Pfizer vaccine as they waited on Moderna’s expected announcement.

Equities also bounded higher after US President-elect Joe Biden’s team pledged not to impose an economically damaging nationwide lockdown to contain the virus, which has infected more than 11 million Americans.